[{"Assets_0_Q2_USD":1643098000.0,"CommonStockSharesOutstanding_0_Q2_shares":302784854.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":293321000.0,"NetIncomeLoss_1_Q2_USD":79042000.0,"NetIncomeLoss_2_Q2_USD":154817000.0,"EarningsPerShareBasic_1_Q2_USD":0.26,"EarningsPerShareBasic_2_Q2_USD":0.51,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":302188000.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":301365000.0,"Ticker":"EXEL","CIK":"939767","name":"EXELIXIS, INC.","OfficialName":"Exelixis Inc. Common Stock","form":"10-Q","period":"20190630","fy":"2019.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"7287350058.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Commercial Physical & Biological Resarch","Market":"NASDAQ","SP500":"nan","filed":"20190731"}]